Disclosure obligation concerning share capital and voting rights at 31 July 2009

Not for publication in the USA, Japan, Canada or Australia	

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen Ø
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com


Copenhagen - 31 July 2009 - As announced on 2 July 2009, TopoTarget A/S (OMX:
TOPO) has completed a capital increase of DKK 66,304,510 nominal value,
corresponding to 66,304,510 shares. The shares were subscribed in cash at DKK 2
per share of DKK 1 nominal value in connection with a fully subscribed rights
issue of new shares with pre-emptive rights to the company's existing
shareholders. See announcement no. 30-09. 

Accordingly, it is hereby notified that TopoTarget A/S had a nominal share
capital at 31 July 2009 of DKK 132,609,020. The share capital consists of one
class of shares, and each share of DKK 1 carries one vote, corresponding to a
total number of voting rights of 132,609,020. 
 

TopoTarget A/S



For further information, please contact:

Peter Buhl Jensen	Telephone	+45 39 17 83 92
CEO		Mobile	+45 21 60 89 22
	



Background information

About TopoTarget 
TopoTarget (OMX: TOPO) is an international biotech company headquartered in
Denmark, dedicated to finding ''Answers for Cancer'' and developing improved
cancer therapies. The company was founded and is run by clinical cancer
specialists and combines years of hands-on clinical experience with in-depth
understanding of the molecular mechanisms of cancer. 
TopoTarget has a broad clinical pipeline but is currently focusing on the
development of belinostat, which has shown proof of concept as monotherapy in
treating haematological malignancies and positive results in solid tumours
where it can be used in combination with full doses of chemotherapy, and is in
phase III in PTCL. TopoTarget's expertise in translational research is
utilizing its highly predictive in vivo and in vitro cancer models. TopoTarget
is directing its efforts on key cancer targets including HDACi, NAD+, mTOR,
FasLigand and topoisomerase II inhibitors. The company's first marketed product
Savene®/Totect® was approved by EMEA in 2006 and the FDA in 2007 and is
marketed by TopoTarget's own sales force in Europe and the US. For more
information, please refer to www.topotarget.com.